Where GLP-1 Trials Fit Into a Care Discussion

A GLP-1 trial percentage answers a narrower question than most people bring to a first appointment. It describes what happened to a defined population receiving a particular treatment under study conditions. Your care discussion also needs to establish what product is being considered, who makes the prescribing decision, which pharmacy fills it, and how problems will be handled. Those delivery details are not footnotes to the evidence: they determine how a treatment plan becomes actual care.

This guide places two major trials alongside documented examples from CoreAge Rx, Ro, Enhance.MD, Sesame, Walgreens and Found. The purpose is not to rank their effectiveness. Neither trial measured these services’ outcomes. Instead, the examples show where research belongs in the journey from consultation to follow-up—and where a provider must supply its own answers. Public documentation was consulted October 19, 2026; that date does not mean every page was updated then.

At a glance

STEP 1 context: STEP 1 studied subcutaneous semaglutide in 1,961 adults without diabetes over 68 weeks, with lifestyle intervention in both groups.
Sources: [3]
SURMOUNT-1 context: SURMOUNT-1 studied subcutaneous tirzepatide in 2,539 adults with obesity or overweight plus a weight-related complication, excluding diabetes, over 72 weeks.
Sources: [4]
Limits of attribution: These trials do not establish outcomes for the reviewed platforms, their compounded preparations, microdoses, vitamin blends or different routes.
Sources: [3] [4]
Compounding boundary: FDA recommends compounded drugs when an individual’s medical needs cannot be met by an FDA-approved drug; compounded preparations are not FDA approved.
Sources: [1]
Delivery safety: FDA advises not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration, and contacting the provider or dispensing pharmacy.
Sources: [1]

Start with the treatment being proposed

Before discussing an expected percentage of weight loss, establish the product and route. CoreAge Rx documents compounded semaglutide administered by subcutaneous injection and says its compounded tirzepatide typically contains B-12; a version without B-12 is something to discuss with the provider. Ro distinguishes an oral Wegovy pill from a Wegovy injection pen. These are meaningful distinctions when matching an offer to research. An ingredient name alone does not establish that the proposed treatment matches a trial.

Enhance.MD markets Core as injectable semaglutide, Advanced as compounded tirzepatide, and Elite as an injectable combination of semaglutide and tirzepatide. Neither STEP 1 nor SURMOUNT-1 establishes outcomes for that combined formulation. Likewise, a microdosing label does not connect an offering to the studied regimens. Use the product and formulation checklist to organize questions about the exact prescription, rather than treating all products sharing an ingredient as one evidence category.

What to match before applying a trial result to a care discussion
Evidence detail	What the trials document	Question for the care team
Population	Adults without diabetes meeting specified weight-related criteria	How does my health history differ from the studied population?
Product and route	Specific subcutaneous semaglutide or tirzepatide study arms	What exact product, formulation and route are proposed?
Duration	68 weeks in STEP 1; 72 weeks in SURMOUNT-1	What follow-up will be available over time?
Tolerability	Adverse events and treatment discontinuations	Who will assess side effects and treatment response?
Applicability	No outcomes measured for these reviewed providers	What evidence supports this particular offering?

Sources: [13] [18] [14] [24] [9] [23] [34] [3] [4]

Read STEP 1 as a complete study, not a headline

STEP 1 was a double-blind randomized trial involving 1,961 adults with obesity or overweight plus a weight-related condition, without diabetes. Over 68 weeks, participants received studied subcutaneous semaglutide 2.4 mg weekly or placebo; both groups received lifestyle intervention. Mean weight change was −14.9% with semaglutide and −2.4% with placebo. The dose identifies the study arm only. It is not an instruction for a reader or a substitute for a prescription.

The tolerability findings belong beside the benefit result. Gastrointestinal events led to discontinuation in 4.5% of the semaglutide group and 0.8% of the placebo group. Novo Nordisk funded the trial. These findings support a discussion about potential benefit and treatment burden within that study context. They do not predict an individual’s response or establish results for a clinic, compounded preparation, oral product, microdose or vitamin blend marketed using the semaglutide name.

Sources: [3]

Keep SURMOUNT-1’s treatment groups separate

SURMOUNT-1 was a double-blind randomized trial of 2,539 adults with obesity or overweight plus a weight-related complication, excluding diabetes, over 72 weeks. Mean weight changes were −15.0%, −19.5% and −20.9% in the studied subcutaneous tirzepatide 5, 10 and 15 mg weekly groups, respectively, compared with −3.1% with placebo. Keeping each percentage attached to its study group prevents the largest result from being presented as the expected result for everyone.

Gastrointestinal adverse events were the most common. Discontinuation because of adverse events occurred in 4.3%, 7.1% and 6.2% of the respective tirzepatide groups, versus 2.6% with placebo. Eli Lilly funded the trial. These doses describe research groups, not treatment recommendations. Comparing the results directly with STEP 1 does not create a randomized head-to-head comparison, and the findings do not establish outcomes for a reviewed provider or its compounded tirzepatide.

Sources: [4] [3]

Bring the evidence to the person making the clinical decision

Research becomes useful when a clinician considers it alongside your health conditions, other medicines, family history, side effects and costs. Platform branding does not identify that decision-maker. CoreAge Rx assigns evaluations, treatment planning and prescribing to three named independent professional entities; its administrative company says it does not practice medicine. Enhance.MD similarly separates administrative support from medical care. Its FAQ describes a team of physicians and nurse practitioners, not an exclusively physician workforce.

The intake process also differs. Ro requests medical history, lifestyle and goals, and may request metabolic testing. Sesame starts with a questionnaire and provider selection, followed by a video consultation; laboratory testing may be ordered if metabolic information is needed. Enhance.MD describes Quest Diagnostics testing before its video consultation, including CMP, TSH, lipids and hemoglobin A1c. Prepare for the first consultation by asking how the study population and proposed product relate to your circumstances—not by asking for a guaranteed trial-sized result.

Sources: [2] [20] [11] [12] [16] [31] [6]

Do not let a trial substitute for pharmacy documentation

A prescription-to-pharmacy handoff introduces questions the trials cannot answer. CoreAge Rx’s FAQ requires its affiliated pharmacy network, while its terms allow a patient-selected pharmacy if requested by email before ordering. That conflict needs clarification. Enhance.MD’s FAQ names Tru Meds Rx, Strive Pharmacy and Pharmacy Hub, but its terms give a partly different list. Its FAQ also permits a chosen pharmacy, with medication billed separately. A platform’s network description does not identify the pharmacy handling your prescription.

For compounded products, FDA recommends use when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Compounded preparations lack FDA approval and premarket review for safety, effectiveness and quality; nonapproval alone does not demonstrate clinical inequivalence. Found says its compounded semaglutide receives third-party potency, purity and sterility testing, but the consulted documentation did not include certificates. The pharmacy handoff guide helps separate such provider claims from patient-specific dispensing information.

Sources: [13] [22] [12] [25] [17] [1]

Separate approval, dispatch and usable delivery

A fast clinical review is not a delivery promise. CoreAge Rx’s FAQ estimates medical feedback in approximately 24 hours, with video consultation or live chat required in certain states. Its policy separately estimates order completion in approximately five to seven business days when documentation is submitted promptly, then arrival approximately two to three business days after pharmacy shipment. These are variable stages, not one guaranteed purchase-to-door deadline. Ro says cash-pay prescriptions routed to its or partner pharmacies ship within a week once prescribed; that is dispatch, not arrival.

Delivery also creates a safety question independent of weight-loss efficacy. FDA explicitly advises not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration, and contacting the provider or dispensing pharmacy. CoreAge Rx’s consulted documentation did not establish precise cold-chain packaging or temperature-excursion procedures. Walgreens’ general same-day and one-to-two-business-day delivery services apply to eligible prescriptions, not a universal GLP-1 promise. Ask who evaluates a questionable shipment and how replacement decisions are made before an order is sent.

Sources: [13] [8] [27] [28] [1]

Ask what follow-up actually delivers

A useful follow-up plan evaluates tolerance and response, not just whether another payment cleared. Ro documents provider messaging, regular check-ins, side-effect management, tracking tools and coaching, but the consulted pages do not establish a message-response deadline. Found describes monthly follow-up for compounded tirzepatide and administration, storage and disposal guidance for compounded semaglutide. Its advertised round-the-clock Aimee access is an AI companion, not continuous human clinical availability. These distinctions matter when deciding whom to contact about a concern.

Walgreens describes most subsequent visits as chat-based, with additional on-demand video available. Follow-up chat visits and additional videos cost $49 each; its pharmacy chat is a different service and availability does not establish a zero fee. CoreAge Rx’s “24/7 Provider Support” heading is explained with customer-support language, which does not establish round-the-clock prescriber access. Use the follow-up and tolerability guide to prepare questions about clinical escalation, expected response times and who can change a treatment plan.

Sources: [2] [7] [30] [5] [17] [29] [19] [28] [26]

Make continuity and payment part of the evidence discussion

NIDDK explains that duration depends on response and side effects, and obesity may require long-term care. That makes the ongoing service arrangement relevant. Ro separates medication costs from membership: $39 for the first month, then $149 monthly on a monthly plan, or as low as $74 per month equivalent with optional annual prepayment. Sesame advertises subscription pricing from $59 monthly with an annual subscription, excluding medication; its $99 month-to-month option is elsewhere described as billed every 28 days rather than each calendar month.

Renewal and cancellation deserve their own questions because stopping payments is not the same as resolving a clinical concern. Sesame’s program page describes self-cancellation before the next cycle, while general terms require email or telephone cancellation at least 48 hours before renewal processing. Found’s insurance pathway requires synchronous video visits before each refill, generally with a separate insurance copay; cash-pay care is mostly asynchronous without a separate visit copay. Those operational differences may affect access even though they cannot establish comparative effectiveness.

Sources: [2] [7] [31] [10] [32]

Questions & answers

Does STEP 1 establish results for CoreAge Rx’s semaglutide microdosing?

No. CoreAge Rx markets a semaglutide microdosing offering, but STEP 1 studied a specific subcutaneous semaglutide regimen, not that service or microdosing product. Ask the clinician what evidence supports the proposed formulation and approach, what limitations remain, and how response will be assessed.

Sources: [15] [3]

Can I use STEP 1’s percentage for an oral product offered through Ro?

Not as an established outcome for that product. Ro describes Wegovy pill as oral semaglutide, whereas STEP 1 studied subcutaneous semaglutide. Shared ingredient identity does not make the routes interchangeable for interpreting this trial. Request evidence relevant to the specific product being discussed.

Sources: [14] [3]

Do the two trials validate Enhance.MD’s Elite combination?

No. Enhance.MD markets Elite as injectable semaglutide plus tirzepatide. STEP 1 and SURMOUNT-1 did not study that combination, so their percentages cannot be added together or used as its measured outcome. Ask what formulation-specific evidence supports the proposal and what uncertainties the clinician considers material.

Sources: [34] [3] [4]

What should I ask Sesame about testing costs?

Ask where testing would occur and whether it is included. Success by Sesame includes Quest Diagnostics lab work except at facilities in Arizona, Hawaii, North Dakota, New Jersey, New York, Oklahoma, Rhode Island, South Dakota and Wyoming. In those states, laboratory fees are additional to the subscription.

Sources: [31]

Is Walgreens’ pharmacy chat the same as a prescriber follow-up?

No. Walgreens separately describes pharmacy-expert chat and Weight Management clinical visits. Pharmacy chat may involve waiting, is not for emergencies and does not replace physician advice. Clinical follow-up chats and additional video visits are advertised at $49 each. Clarify which service can address the particular issue.

Sources: [28] [19]

Does Found’s “with insurance” compounded price mean insurance covers the drug?

No. Found’s billing consent makes patients responsible for compounded GLP-1 charges and prohibits submitting those amounts to insurance. Its insurance pricing reflects coverage for clinical care, with possible copays, coinsurance and deductibles. Ask for the medication, membership, visits and laboratory charges to be distinguished before enrollment.

Sources: [33] [21]

Our assessment

STEP 1 and SURMOUNT-1 provide valuable evidence about benefits and tolerability under defined research conditions. Their proper role is to inform a clinician-led discussion, not to serve as a performance guarantee for a platform. The reviewed services document different consultation, pharmacy and follow-up arrangements, sometimes with unresolved contradictions. A well-prepared care conversation connects the exact proposed product to relevant research, identifies responsibility at each handoff, and establishes how tolerance, response and continuity will be reviewed. Clear documentation cannot guarantee an individual result, but it makes the remaining uncertainties easier to discuss.

FOLLOW THE EVIDENCE

Read the underlying science

These articles explain the study populations, measurements and limitations behind the practical questions in this guide.

SELECT Beyond Weight Loss: What the Heart Outcomes Mean for Ongoing Care
Semaglutide reduced a major cardiovascular composite in people with established cardiovascular disease and no diabetes. Understanding the endpoint, absolute difference, and treatment discontinuations is essential to interpreting that benefit.
STEP-HFpEF: What Better Symptoms and Walking Distance Mean for Continuing Care
The 529-person trial connected semaglutide with better heart-failure symptom scores, greater weight loss, and improved walking performance over 52 weeks. Understanding those endpoints helps separate meaningful clinical evidence from claims about survival, products, or care programs.
What Tirzepatide’s Fat and Lean Mass Results Mean for Ongoing Care
The SURMOUNT-1 DXA substudy found that most lost weight was fat, but lean tissue also declined. Understanding the denominators—and what the scans did not measure—is essential to interpreting the result.

Explore the science library →

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Where GLP-1 Trials Fit Into a Care Discussion

At a glance

01Start with the treatment being proposed

02Read STEP 1 as a complete study, not a headline

03Keep SURMOUNT-1’s treatment groups separate

04Bring the evidence to the person making the clinical decision

05Do not let a trial substitute for pharmacy documentation

06Separate approval, dispatch and usable delivery

07Ask what follow-up actually delivers

08Make continuity and payment part of the evidence discussion